In the published article, there was an error in the legend for Figure 2 as published. Furthermore, we have made the wrong graphical representation for Figure 2. The corrected figure and its legend appear below.
Figure 2
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
furmonertinib, non-small cell lung cancer, EGFR-mutated, epidermal growth factor, receptor, real-world setting
Citation
Yan N, Guo S, Huang S, Zhang H and Li X (2024) Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience. Front. Oncol. 14:1412472. doi: 10.3389/fonc.2024.1412472
Received
05 April 2024
Accepted
28 May 2024
Published
03 June 2024
Volume
14 - 2024
Edited and reviewed by
Santiago Viteri, Clínica Mi Tres Torres, Spain
Updates
Copyright
© 2024 Yan, Guo, Huang, Zhang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xingya Li, lixingya0925@vip.163.com; Huixian Zhang, huixianeight@163.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.